The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
News|Articles|October 11, 2023
Nirsevimab Shows Sustained Efficacy in Infants Through Full RSV Season
Author(s)Alicia Bigica
The monoclonal antibody demonstrated a significant impact on RSV-related hospitalizations regardless of infant characteristics.
Advertisement
Data presented in Boston at
The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
In a presentation, Saul N. Faust, FRCPCH, PhD, of the University of Southampton and University Hospital Southampton NHS Foundation Trust, recounted data from the HARMONIE clinical trial conducted in the United Kingdom, France, and Germany that included 8058 infants who were randomly assigned to receive nirsevimab (n=4037) or no intervention (n=4021). Infants were at least 29 weeks gestational age, and those in the intervention group received a single intramuscular injection of nirsevimab (<5 kg 50 mg; ≥5 kg 100 mg) before or during the RSV season, and were monitored for all-cause lower respiratory tract infection.
Overall, nirsevimab demonstrated an 83.21% efficacy in preventing RSV LRTI, with a confidence interval of 67.77-92.04%. This efficacy was observed across various infant subgroups, including those who were born at term (≥37 weeks) or prematurely (<37 weeks), with nirsevimab displaying efficacy rates of 84.41% (CI, 64.92-94.10%) and 78.31% (CI, 33.49-94.69%), respectively. Additionally, the weight of infants at randomization, whether below 5 kg or 5 kg or greater, had no discernible impact on nirsevimab's effectiveness, with efficacy rates of 82.12% (CI, 59.14-93.30%) and 85.16% (CI, 57.01-96.25%) reported, respectively.
Notably, nirsevimab's impact on all-cause LRTI hospitalizations was 58.04% (CI, 39.69-71.19%), which underscores the broader potential of nirsevimab in mitigating the overall burden of LRTIs in infants.
The introduction of nirsevimab to the RSV treatment landscape, in addition to the
REFERENCE
Faust SN, Cathie K, Drysdale SB, et al. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study. Presented at: IDWeek 2023. October 11-14, 2023; Boston, MA. Abstract 89.
Advertisement
Related to this article
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
In its second disease cluster this summer, city officials are cleaning building towers in the South Bronx amidst an ongoing investigation and are rolling out measures to prevent future Legionnaires' cases.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
16 years after the FDA determined that it does not, a new analysis of trials comparing cefepime with other ß-lactams, including the unpublished industry sponsored trials reviewed by the FDA, disagrees.